Clinical trials: Sunitinib
Metastatic Prostate Cancer
Phase II Sunitinib Prog Met AIPC
The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.
- Trial name
- NCT00599313
- Testing
- Sunitinib
- Where
- 45 sites in United States
- Volunteers
- 36 people
- Sponsor
- US Oncology Research
Non Small Cell Lung Cancer
Sunitinib Non Small Cell Lung Cancer Patients Over 70
The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.
- Trial name
- NCT00864721
- Testing
- Sutent
- Where
- 13 sites in United States
- Volunteers
- 63 people
- Sponsor
- US Oncology Research
Carcinoma, Renal Cell
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
This is for subjects with metastatic Renal Cell Cancer (RCC). There are four Food and Drug Administration (FDA) approved drugs for first-line therapy of Renal Cell Cancer (RCC) and two for second-line therapy.
- Trial name
- NCT02560012
- Testing
- Sunitinib, Temsirolimus, Sorafenib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- The University of Texas Health Science Center, Houston
Kidney Neoplasms
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
To compare the disease free survival time and safety of sunitinib with placebo in adjuvant treatment patients at high risk of recurrent kidney cancer after surgery.
- Trial name
- S-TRAC (NCT00375674)
- Testing
- Sunitinib malate
- Where
- 115 sites in United States, Australia and 20 more
- Volunteers
- 674 people
- Sponsor
- Pfizer
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01158222
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Case Comprehensive Cancer Center
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes
Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
This phase II trial is studying how well sunitinib works in treating patients with myelodysplastic syndromes or chronic myelomonocytic leukemia.
- Conditions
- Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
- Trial name
- NCT00451048
- Testing
- sunitinib malate
- Where
- 4 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Fallopian Tube Cancer
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
The purpose of this study is to determine the effectiveness of sunitinib on participants with ovarian, fallopian tube or peritoneal cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT00768144
- Testing
- Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dana-Farber Cancer Institute
Urothelial Cancer, Bladder Cancer
SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial
The purpose of this study is to find out if SU011248 works and if it is safe in patients with advanced transitional cell carcinoma.
- Conditions
- Urothelial Cancer, Bladder Cancer, Adult
- Trial name
- SPRUCE (NCT00578526)
- Testing
- SU011248
- Where
- 5 sites in Canada
- Volunteers
- 64 people
- Sponsor
- AHS Cancer Control Alberta
Renal Cell Carcinoma
Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)
Combined sunitinib and bevacizumab in advanced renal cell carcinoma.
- Trial name
- NCT02919371
- Testing
- Sunitinib, Bevacizumab
- Where
- Saudi Arabia
- Volunteers
- 77 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Lung Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00748163
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, sunitinib malate
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lung Cancer
Sunitinib Malate in Treating Patients With Small Cell Lung Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00953459
- Testing
- sunitinib malate, laboratory biomarker analysis, fludeoxyglucose F 18
- Where
- Netherlands
- Volunteers
- 9 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Renal Cell, Kidney Diseases
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and sunitinib. The study will enroll patients with metastatic clear cell renal cell carcinoma.
- Conditions
- Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms
- Trial name
- NCT02386111
- Testing
- Combination of varlilumab and sunitinib
- Where
- 9 sites in United States
- Volunteers
- 17 people
- Sponsor
- Celldex Therapeutics
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00891878
- Testing
- capecitabine, sunitinib malate
- Where
- 182 sites in United States
- Volunteers
- 12 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Glioblastoma, Gliosarcoma
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
This is a study to determine the efficacy, safety and clinical benefit (how well the drugs works), of the pharmaceutical compositions in Nasal Spray NST-4G for the treatment of brain tumors( Recurrent Glioblastoma…
- Conditions
- Recurrent Glioblastoma, Gliosarcoma, Anaplastic Gliomas
- Trial name
- NCT03275558
- Testing
- Axitinib 1 MG, Sunitinib 5 MG, Pazopanib 5 MG
- Where
- 2 sites in Hong Kong, Singapore
- Sponsor
- Center Trials & Treatment
Cancer
Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Cancer is the second leading cause of death in the United States, with approximately 90% of deaths resulting from patients with metastatic spread.
- Trial name
- NCT00463060
- Testing
- sunitinib malate (Sutent), radiotherapy
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Ovarian Cancer, Adverse Effects
Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
Patients with early and advanced stages of epithelial ovarian cancer are treated with postoperative systemic chemotherapy after appropriate surgical staging and cytoreductive surgery.
- Trial name
- NCT01824615
- Testing
- Sunitinib
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Cathay General Hospital
Renal Cell Carcinoma
A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
This is a multi-national, phase II, single arm study to explore the safety/efficacy and potential biomarkers on sunitinib 2/1 schedule for Asian patients with advanced renal cell carcinoma.
- Trial name
- NCT02626754
- Testing
- Sunitinib malate
- Where
- 7 sites in Taiwan
- Volunteers
- 13 people
- Sponsor
- vghtpe user
Advanced Renal Cell Carcinoma, Renal Cell Carcinoma
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated…
- Conditions
- Advanced Renal Cell Carcinoma, Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
- Trial name
- ADAPT (NCT01582672)
- Testing
- Standard Treatment, AGS-003
- Where
- 125 sites in United States, Canada and 6 more
- Volunteers
- 462 people
- Sponsor
- Argos Therapeutics
Renal Cell Cancer, Metastatic Renal Cell Cancer
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable.
- Trial name
- NCT01829841
- Testing
- Famitinib, Sunitinib
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00824538
- Testing
- sunitinib malate, flow cytometry, immunohistochemistry staining method
- Volunteers
- 13 people
- Sponsor
- University of California, San Francisco